The ACTH-Cortisol Axis: How a Peptide Controls Stress

Stress & Adrenal Peptides

39 amino acids

ACTH (adrenocorticotropic hormone) is a 39-amino-acid peptide cleaved from the POMC precursor in the anterior pituitary. It travels through the bloodstream to the adrenal cortex, where it triggers cortisol synthesis within minutes of a stressor.

Herman et al., Comprehensive Physiology, 2016

Herman et al., Comprehensive Physiology, 2016

View as image

When you encounter a threat, your hypothalamus releases corticotropin-releasing hormone (CRH), a 41-amino-acid peptide that travels a few millimeters through the hypophyseal portal system to the anterior pituitary. There, CRH triggers corticotrope cells to release adrenocorticotropic hormone (ACTH), a 39-amino-acid peptide, into the systemic circulation. ACTH reaches the adrenal cortex within seconds and stimulates cortisol synthesis and secretion within minutes. Cortisol then feeds back to the hypothalamus and pituitary to suppress further CRH and ACTH release, completing a negative feedback loop that prevents runaway stress activation.^[1]

This hypothalamic-pituitary-adrenal (HPA) axis is the body's central stress response system. Every component is a peptide or a peptide-regulated process. CRH is a peptide. ACTH is a peptide. Even cortisol's production is controlled by a peptide signal. Understanding the ACTH-cortisol axis is foundational to understanding how peptide hormones regulate physiology under stress, and what happens when the axis malfunctions.

For a deeper examination of the feedback loop mechanics, see How CRH, ACTH, and Cortisol Form a Peptide Feedback Loop. For the opioid peptides co-produced alongside ACTH, see Adrenal Enkephalins: Opioid Peptides from Your Stress Glands.

POMC: The Precursor That Produces Everything

ACTH does not exist in isolation. It is one product of pro-opiomelanocortin (POMC), a 241-amino-acid precursor protein synthesized in corticotrope cells of the anterior pituitary. POMC processing by prohormone convertases yields multiple biologically active peptides, and which peptides are produced depends on the tissue and the specific convertases expressed.

In the anterior pituitary, prohormone convertase 1 (PC1) cleaves POMC into:

• ACTH (1-39): The adrenal-stimulating peptide
• Beta-lipotropin: A lipid-mobilizing peptide that is further cleaved to produce beta-endorphin
• N-terminal POMC fragment: Contains gamma-MSH

In the hypothalamus and intermediate lobe (where present), prohormone convertase 2 (PC2) further processes ACTH into:

• Alpha-MSH (ACTH 1-13): Melanocyte-stimulating hormone, involved in appetite suppression, skin pigmentation, and immune modulation
• CLIP (ACTH 18-39): Corticotropin-like intermediate lobe peptide

This shared precursor means that stress-induced POMC processing simultaneously produces ACTH (to mount the cortisol response), beta-endorphin (to modulate pain), and alpha-MSH (to suppress appetite). The stress response is not a single hormone event. It is a coordinated multi-peptide program launched from a single precursor molecule.^[2]

Fujima et al. (2020) demonstrated that POMC accumulation in the pituitary, when processing is impaired, affects food intake and energy balance, illustrating how tightly coupled POMC cleavage is to metabolic regulation.^[3] See Beta-Endorphin: The Runner's High Peptide for the co-produced opioid peptide.

CRH: The Trigger Peptide

Corticotropin-releasing hormone (CRH, also called CRF) is a 41-amino-acid peptide synthesized in the paraventricular nucleus (PVN) of the hypothalamus. It is the primary activator of the HPA axis. CRH binds CRH receptor type 1 (CRHR1) on anterior pituitary corticotropes, activating adenylate cyclase, raising intracellular cAMP, and stimulating ACTH secretion.

Vasconcelos et al. (2020) reviewed CRH receptor signaling comprehensively, noting that CRHR1 and CRHR2 have distinct tissue distributions and functions.^[4] CRHR1 mediates the acute stress response. CRHR2, expressed more broadly in peripheral tissues and specific brain regions, appears to modulate stress recovery and feeding behavior. The balance between CRHR1 and CRHR2 activation may determine whether a stress response is adaptive (brief, resolved) or maladaptive (prolonged, pathological).

Arginine vasopressin (AVP) acts as a co-secretagogue with CRH. AVP alone is a weak ACTH stimulator, but it potentiates CRH's effect through a different signaling pathway (phospholipase C and calcium rather than cAMP). Beurel and Bhatt (2014) documented this synergy and showed that chronic stress shifts the CRH:AVP ratio in the PVN, with AVP becoming proportionally more important in sustained stress states.^[5] This shift may explain why the HPA axis response changes qualitatively during chronic versus acute stress.

Sukhareva (2021) reviewed the role of CRH and its receptors in stress regulation, highlighting that CRH signaling extends far beyond the HPA axis to include direct effects on anxiety behavior, gut motility, and immune function.^[6]

ACTH at the Adrenal: The MC2R Signaling Cascade

ACTH reaches the adrenal cortex through the systemic circulation and binds the melanocortin-2 receptor (MC2R), a G-protein-coupled receptor expressed exclusively on adrenocortical cells. MC2R requires a specific accessory protein, MRAP (melanocortin-2 receptor accessory protein), for proper folding and cell-surface expression. Without MRAP, MC2R is trapped in the endoplasmic reticulum and cannot respond to ACTH. Mutations in MRAP cause familial glucocorticoid deficiency type 2, a condition in which the adrenal glands cannot respond to ACTH despite normal ACTH levels.

ACTH-MC2R binding activates adenylate cyclase, raising intracellular cAMP and activating protein kinase A (PKA). PKA phosphorylates hormone-sensitive lipase, which mobilizes cholesterol from lipid droplets. PKA also activates steroidogenic acute regulatory protein (StAR), which transports cholesterol from the outer to the inner mitochondrial membrane. There, the enzyme CYP11A1 (cholesterol side-chain cleavage enzyme) catalyzes the rate-limiting step in steroidogenesis: converting cholesterol to pregnenolone.

From pregnenolone, a series of enzymatic reactions in the zona fasciculata produces cortisol (in humans) or corticosterone (in rodents). The entire process, from ACTH binding to cortisol appearance in the bloodstream, takes approximately 2-5 minutes. This speed is possible because the enzymatic machinery is constitutively expressed; ACTH's role is to provide the substrate (cholesterol) and activate the rate-limiting transport step, not to build new enzymes from scratch.

ACTH also has trophic effects on the adrenal cortex. Sustained ACTH stimulation causes adrenal hypertrophy (enlarged glands with increased cortisol-producing capacity), while ACTH deficiency causes adrenal atrophy. This is clinically relevant: patients on long-term exogenous glucocorticoids (prednisone, dexamethasone) suppress ACTH through negative feedback, causing adrenal atrophy. Abrupt withdrawal of the exogenous glucocorticoid can precipitate adrenal crisis because the atrophied glands cannot mount an adequate cortisol response.

The Negative Feedback Loop

Cortisol feeds back to suppress its own production at two levels:

Fast feedback (seconds to minutes): Non-genomic cortisol actions at the hypothalamus rapidly suppress CRH release. This involves membrane-associated glucocorticoid receptors and endocannabinoid signaling in the PVN. The fast feedback limits the initial burst of HPA activation.

Slow feedback (60-90 minutes to hours): Cortisol enters cells, binds the cytoplasmic glucocorticoid receptor (GR), and the cortisol-GR complex translocates to the nucleus. There, it binds glucocorticoid response elements (GREs) in the promoters of the CRH and POMC genes, suppressing their transcription. This genomic mechanism provides sustained suppression of the HPA axis after the stressor has resolved.

The hippocampus is a critical node in negative feedback. It expresses high levels of both glucocorticoid receptors (GR, which binds cortisol at high concentrations) and mineralocorticoid receptors (MR, which binds cortisol at basal concentrations). The hippocampus inhibits the PVN, and cortisol binding to hippocampal GR strengthens this inhibition. Chronic stress and elevated cortisol can damage hippocampal neurons, weakening the inhibitory signal and creating a vicious cycle: stress damages the feedback mechanism, leading to more cortisol, leading to more hippocampal damage.^[1]

Kozicz (2008) demonstrated that chronic psychosocial stress alters CRH expression in the PVN and co-localizes changes with urocortin 1, another CRH family peptide, suggesting that chronic stress remodels the peptide signaling architecture of the hypothalamus itself.^[7]

What Cortisol Actually Does

Cortisol is often called the "stress hormone," but this label obscures the breadth of its physiological roles. Cortisol is a glucocorticoid steroid hormone with effects on virtually every organ system.

Metabolic effects: Cortisol raises blood glucose by stimulating hepatic gluconeogenesis (making new glucose from amino acids and glycerol), inhibiting peripheral glucose uptake in muscle, and promoting lipolysis in adipose tissue. This metabolic mobilization makes energy substrates available during stress. In chronic excess, these same effects produce hyperglycemia, insulin resistance, central fat deposition, and muscle wasting.

Immune effects: At physiological levels, cortisol modulates the immune response by shifting the T-helper cell balance from Th1 (pro-inflammatory) toward Th2 (anti-inflammatory). At pharmacological levels, it broadly suppresses immune function, which is why synthetic glucocorticoids (prednisone, dexamethasone) are used as immunosuppressants. The immune-modulatory effect of cortisol explains why chronic stress increases susceptibility to infections and why acute stress can temporarily suppress inflammatory symptoms.

Bone and connective tissue: Cortisol inhibits osteoblast activity and promotes osteoclast-mediated bone resorption. It reduces collagen synthesis in skin and connective tissue. These effects are minimal during normal circadian cortisol fluctuations but become clinically significant in Cushing's syndrome or during chronic glucocorticoid therapy, producing osteoporosis and thin, fragile skin.

Cardiovascular effects: Cortisol potentiates the vasoconstrictor effects of catecholamines (epinephrine, norepinephrine), maintaining blood pressure during stress. Cortisol deficiency produces hypotension, and cortisol excess produces hypertension.

Brain effects: Cortisol crosses the blood-brain barrier and acts on glucocorticoid and mineralocorticoid receptors in the hippocampus, amygdala, and prefrontal cortex. Acute cortisol enhances memory consolidation (stress-related memories are stored preferentially). Chronic cortisol impairs hippocampal neurogenesis, reduces dendritic branching, and may contribute to depression and cognitive decline.

Circadian Rhythm: ACTH Is Not Constant

ACTH and cortisol are not released only during stress. They follow a robust circadian rhythm, with peak levels in the early morning (6-8 AM) and a nadir around midnight. This rhythm is driven by the suprachiasmatic nucleus (SCN) of the hypothalamus, the master circadian clock, which entrains CRH release in the PVN.

The morning cortisol peak serves a metabolic function: it mobilizes glucose, increases blood pressure, and prepares the body for the energetic demands of waking. The cortisol awakening response (CAR), a further surge occurring 30-45 minutes after waking, is one of the most robust biomarkers of HPA axis function.

Beyond the circadian rhythm, ACTH and cortisol are released in ultradian pulses approximately every 60-90 minutes throughout the day. These pulses are generated by an intrinsic oscillator in the hypothalamus-pituitary-adrenal circuit and are essential for maintaining glucocorticoid receptor sensitivity. Constant (non-pulsatile) cortisol exposure desensitizes the GR, while pulsatile exposure maintains responsiveness. This pulsatile pattern is disrupted in major depression, Cushing's syndrome, and chronic fatigue syndrome, suggesting that the temporal pattern of cortisol release matters as much as the total amount.

Neuropeptide Y (NPY), a stress-resilience peptide, interacts with the circadian ACTH rhythm. Antonijevic et al. (2000) showed that NPY administration promotes sleep and simultaneously inhibits both ACTH and cortisol release in young men, demonstrating how neuropeptides can modulate the HPA axis independently of the CRH trigger.^[8] See Neuropeptide Y: The Stress Resilience Peptide for more on this counter-regulatory peptide.

When the Axis Breaks: Clinical Disorders

Cushing's Syndrome (ACTH-Dependent)

When a pituitary adenoma secretes excessive ACTH (Cushing's disease) or an ectopic tumor produces ACTH (ectopic ACTH syndrome), the result is sustained hypercortisolism. Symptoms include central obesity, moon facies, skin thinning, osteoporosis, hyperglycemia, hypertension, and immune suppression. The negative feedback loop is overridden because the adenoma or tumor is autonomous and does not respond to cortisol suppression.

Machado et al. (2007) examined the in vivo response to growth hormone-releasing peptide-6 (GHRP-6) in ACTH-dependent Cushing's syndrome, finding that GHRP-6 stimulated ACTH release from corticotrope adenomas, suggesting shared regulatory pathways between the GH and ACTH axes.^[9]

Adrenal Insufficiency

Primary adrenal insufficiency (Addison's disease) results from destruction of the adrenal cortex, typically by autoimmune attack. ACTH levels are elevated (the pituitary is trying to stimulate non-functional adrenals), and cortisol is low. Secondary adrenal insufficiency results from pituitary failure (ACTH is low) or, most commonly, from prolonged exogenous glucocorticoid use that suppresses the HPA axis.

The distinction between primary and secondary insufficiency is clinically important because treatment differs. Both require cortisol replacement, but primary insufficiency also requires mineralocorticoid replacement (fludrocortisone) because the entire adrenal cortex is damaged, not just the cortisol-producing zona fasciculata. In secondary insufficiency, the zona glomerulosa (which produces aldosterone) remains functional because it is regulated primarily by the renin-angiotensin system, not ACTH.

Iatrogenic HPA Suppression

The most common cause of HPA axis dysfunction is not disease but medication. Exogenous glucocorticoids (prednisone, dexamethasone, inhaled corticosteroids at high doses) suppress CRH and ACTH through negative feedback. With prolonged use, the adrenal glands atrophy from disuse. Tapering glucocorticoids gradually allows the HPA axis to recover, but full recovery can take months. Abrupt withdrawal risks adrenal crisis: life-threatening hypotension, hypoglycemia, and cardiovascular collapse from the inability to produce cortisol.

HPA Dysregulation in Metabolic Disease

The HPA axis interacts bidirectionally with metabolic disease. Obesity is associated with subtle HPA axis hyperactivation: normal or slightly elevated cortisol production rates with altered cortisol metabolism and tissue-specific glucocorticoid receptor expression. Kim et al. (1999) showed that diabetes decreases POMC mRNA expression in both the arcuate nucleus and pituitary, while insulin normalizes it, directly linking glycemic control to the POMC-ACTH production pathway.^[2] This connection suggests that metabolic state and stress hormone production are not independent systems but form a tightly coupled regulatory network.

The clinical test for adrenal function is the ACTH stimulation test (cosyntropin test), which uses synthetic ACTH(1-24) (cosyntropin/Synacthen) to stimulate the adrenal glands. A normal cortisol response to exogenous ACTH confirms adrenal reserve. A blunted response indicates adrenal insufficiency. This diagnostic test illustrates a practical application of peptide biology: synthetic ACTH fragments retain full adrenal-stimulating activity because the first 24 amino acids of ACTH contain the complete receptor-binding domain.^[10]

ACTH Fragments: Neuroprotection Without Adrenal Stimulation

One of the most pharmacologically interesting aspects of ACTH is that different fragments of the 39-amino-acid peptide have distinct biological activities. The adrenal-stimulating activity resides in ACTH(1-24). But the fragment ACTH(4-10) has no adrenal-stimulating activity yet retains neuroprotective and cognitive-enhancing properties.

Semax, a synthetic heptapeptide analog of ACTH(4-10) with a C-terminal Pro-Gly-Pro extension for stability, has been studied extensively in Russian neuropharmacology. Dolotov et al. (2006) showed that Semax regulates BDNF (brain-derived neurotrophic factor) and TrkB expression in the rat brain, suggesting a mechanism for its cognitive effects that is independent of cortisol or adrenal function.^[11]

Inozemtseva et al. (2024) compared Semax with another ACTH(4-10) analog (Mexidol) for antidepressant-like and antistress effects, finding that both compounds reduced behavioral markers of stress and depression in animal models without stimulating cortisol release.^[12]

These findings demonstrate a recurring theme in peptide biology: precursor proteins generate multiple fragments with distinct and sometimes opposing functions. ACTH activates the stress response; ACTH(4-10) analogs may help the brain recover from stress. Both come from the same precursor molecule.

Semax is approved in Russia and some post-Soviet states for conditions including stroke recovery, cognitive impairment, and stress-related disorders. It has not undergone FDA review and is not approved in the United States or European Union. The peptide is available through research suppliers and some compounding pharmacies.

The GH-ACTH Crossroad

Growth hormone-releasing peptides (GHRPs) interact with the HPA axis in unexpected ways. Arvat et al. (1997) showed that GHRP-2 and hexarelin stimulate not just growth hormone release but also ACTH and cortisol secretion, though through mechanisms distinct from CRH.^[9] The ACTH response to GHRPs appears to involve hypothalamic AVP and possibly direct pituitary effects. This cross-talk means that growth hormone secretagogue peptides cannot be considered in isolation from the stress axis.

De Vriese et al. (2010) extended this observation, showing that ghrelin, the endogenous GHS receptor ligand, also stimulates ACTH and cortisol release when administered in physiological amounts.^[9] The ghrelin-ACTH connection provides a mechanistic link between metabolic status (ghrelin rises during fasting) and stress hormone activation, explaining part of why caloric deprivation activates the HPA axis.

For the broader relationship between neuropeptides and mood disorders, see Neuropeptides and Depression: The Biology Beyond Serotonin.

The Bottom Line

The ACTH-cortisol axis is a peptide-driven cascade in which CRH from the hypothalamus triggers ACTH release from the pituitary, and ACTH stimulates cortisol synthesis in the adrenal cortex through the MC2R receptor. The system is regulated by negative feedback (cortisol suppresses CRH and ACTH), circadian entrainment, and interactions with other neuropeptides including AVP and NPY. ACTH derives from the POMC precursor alongside beta-endorphin and alpha-MSH, linking stress to pain modulation and metabolism. Dysregulation produces Cushing's syndrome (excess) or adrenal insufficiency (deficit). ACTH fragments like ACTH(4-10) retain neuroprotective properties without adrenal stimulation, opening a pharmacological space distinct from the stress response itself.

Frequently Asked Questions

What does ACTH do in the body?

ACTH (adrenocorticotropic hormone) is a 39-amino-acid peptide released from the anterior pituitary in response to stress. It travels through the bloodstream to the adrenal cortex, where it binds the MC2R receptor and triggers cortisol synthesis within 2-5 minutes. ACTH also has trophic effects: sustained levels cause adrenal gland growth, while deficiency causes adrenal atrophy. It is one of several peptides cleaved from the POMC precursor protein.

What is the HPA axis?

The hypothalamic-pituitary-adrenal (HPA) axis is the body's central stress response system. The hypothalamus releases CRH (corticotropin-releasing hormone), which triggers the pituitary to release ACTH, which triggers the adrenal glands to release cortisol. Cortisol then feeds back to suppress CRH and ACTH, completing a negative feedback loop. The HPA axis also follows a circadian rhythm, with cortisol peaking in the early morning and reaching its lowest levels around midnight.

What happens when ACTH is too high?

Chronically elevated ACTH, typically from a pituitary adenoma (Cushing's disease) or ectopic ACTH-producing tumor, drives excessive cortisol production. This causes central obesity, muscle wasting, thin skin that bruises easily, high blood sugar, high blood pressure, osteoporosis, and immune suppression. The condition is called ACTH-dependent Cushing's syndrome. Diagnosis involves measuring ACTH and cortisol levels, and treatment typically requires surgical removal of the adenoma.

What is the ACTH stimulation test?

The ACTH stimulation test (cosyntropin test) uses synthetic ACTH(1-24) injected intravenously to assess whether the adrenal glands can produce cortisol normally. Blood cortisol is measured 30 and 60 minutes after injection. A cortisol level above 18-20 mcg/dL indicates adequate adrenal reserve. A blunted response suggests adrenal insufficiency. The test works because the first 24 amino acids of ACTH contain the complete receptor-binding domain needed for adrenal stimulation.

What is POMC and why does it matter?

POMC (pro-opiomelanocortin) is a 241-amino-acid precursor protein produced in the anterior pituitary. Enzymatic cleavage of POMC generates ACTH, beta-endorphin (an endogenous opioid), alpha-MSH (which suppresses appetite and affects pigmentation), and beta-lipotropin. This means the stress response simultaneously produces hormones for cortisol regulation, pain modulation, appetite control, and lipid metabolism from a single precursor molecule.

Can ACTH fragments improve brain function?

The ACTH(4-10) fragment has no adrenal-stimulating activity but retains neuroprotective properties. Semax, a synthetic analog of ACTH(4-10), upregulates BDNF expression in the brain and shows antidepressant-like and antistress effects in animal models without affecting cortisol levels (Dolotov et al., 2006; Inozemtseva et al., 2024). This demonstrates that different regions of the ACTH peptide serve distinct biological functions, and that neuroprotection can be separated from stress hormone activation.